Inactive Instrument

News Numinus Wellness Inc. Toronto S.E.

Equities

NUMI

CA67054W1032

Biotechnology & Medical Research

All News

25-01-13	Numinus Provides Bi-Weekly Update on Annual Filings	PR
25-01-01	Numinus Provides Bi-Weekly Update on Annual Filings	PR
24-12-16	Numinus Provides Bi-Weekly Update on Annual Filings	PR
23-12-13	Numinus Congratulates MAPS on its Application to the FDA for MDMA-Assisted Therapy for PTSD	PR
23-10-03	Numinus Announces Psychedelic Program for Mental Distress Associated with Chronic and Serious Illness through Cedar Clinical Research	PR
23-09-25	Numinus Wellness Inc. Announces At-The-Market Offering Equity Program	PR
23-06-14	Numinus Appoints New Chief Financial Officer	PR
23-06-05	Cedar Clinical Research, by Numinus, the top enrolling clinical research site for MindMed's Phase 2B study evaluating MM-120	PR
23-03-27	Numinus Launches the Practitioner Certification Pathway - a Complete Psychedelic-Assisted Therapy Training Program	PR
23-02-15	Numinus Wellness Announces Voting Results From its Annual General and Special Meeting of Shareholders	PR
22-11-01	Numinus Re-Launches "Psychedelic Therapy Frontiers" Podcast with additional hosts and topics	PR
22-07-14	Numinus Wellness Inc. Reports Q3 2022 Results	PR
22-06-10	Numinus completes acquisition of Novamind and announces executive appointments	PR
22-04-14	Numinus Wellness Inc. Reports Q2 2022 Results	PR
22-02-01	Numinus Appoints New Bioscience Advisors to Advance IP Development	PR
22-01-20	Numinus Wellness Inc. Reports Q1 2022 Results	PR
21-12-09	Numinus Wellness Inc. Reports Q4 and Year End 2021 Results	PR
21-11-22	Numinus to Host Q4 and 2021 Annual Results Conference Call on December 9, 2021	PR
17-06-19	IIROC Trade Halt - Rojo Resources Ltd.	NE
17-05-28	Reverse Split: 1 of 5	FA